About: Evaluation of infliximab as second-line treatment of acute graft versus host disease -validating response on day 7 and 28 as predictors of survival   Goto Sponge  NotDistinct  Permalink

An Entity of Type : owl:Thing, within Data Space : wasabi.inria.fr associated with source document(s)

AttributesValues
value
  • Evaluation of infliximab as second-line treatment of acute graft versus host disease -validating response on day 7 and 28 as predictors of survival
Subject
  • Therapy
  • Monoclonal antibodies
  • Medicinal chemistry
  • Health policy
  • Drug discovery
  • Pharmaceutical sciences
  • TNF inhibitors
  • Noninfectious immunodeficiency-related cutaneous conditions
  • Complications of surgical and medical care
  • Immune system disorders
  • Immunosuppressants
  • Transplantation medicine
  • Engineered proteins
  • Janssen Pharmaceutica
  • Janssen Biotech
  • Merck & Co. brands
  • Schering-Plough brands
  • Johnson & Johnson brands
part of
is hasSource of
is resource representing a document's title of
Faceted Search & Find service v1.13.91 as of Mar 24 2020


Alternative Linked Data Documents: Sponger | ODE     Content Formats:       RDF       ODATA       Microdata      About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data]
OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software